Profile data is unavailable for this security.
About the company
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
- Revenue in GBP (TTM)16.81bn
- Net income in GBP2.14bn
- Incorporated1992
- Employees61.10k
- LocationAstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 20 7304 5000
- Fax+44 20 7604 8151
- Websitehttps://www.astrazeneca.com/Home
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Daiichi Sankyo Co Ltd | 23.51% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 5.11bn | 726.00m | 21.51bn | 14.62k | 27.97 | 3.45 | -- | 4.21 | 10.33 | 10.33 | 74.57 | 83.83 | 0.4952 | -- | -- | 349,227.00 | 7.06 | 4.49 | 8.68 | 5.69 | 35.81 | 30.83 | 14.26 | 8.04 | 0.7161 | 5.09 | 0.4044 | 45.20 | 23.55 | 5.40 | 141.20 | 33.07 | 7.79 | 6.67 |
| Shire PLC | 11.60bn | 1.56bn | 39.67bn | 23.04k | 25.35 | 1.41 | 11.77 | 3.42 | 1.71 | 3.69 | 12.72 | 30.76 | 0.2291 | 1.35 | 5.37 | 503,542.40 | 3.07 | 5.93 | 3.43 | 6.95 | 70.65 | 74.65 | 13.40 | 19.32 | 0.6587 | 8.40 | 0.3312 | 11.80 | 33.03 | 27.34 | 205.47 | 18.00 | 32.84 | 14.56 |
| AstraZeneca plc | 16.81bn | 2.14bn | 69.54bn | 61.10k | 32.51 | 7.12 | 15.90 | 4.14 | 1.69 | 1.67 | 13.26 | 7.71 | 0.358 | 1.48 | 4.39 | 275,059.70 | 4.35 | 4.38 | 6.20 | 6.04 | 80.29 | 80.84 | 12.15 | 10.56 | 0.545 | 3.48 | 0.5767 | 134.09 | -2.33 | -4.29 | -13.38 | -13.45 | -18.91 | -10.26 |
| GlaxoSmithKline plc | 30.02bn | 2.11bn | 78.17bn | 98.46k | 36.78 | -- | 18.50 | 2.60 | 0.4285 | 0.2081 | 6.11 | -0.0139 | 0.5204 | 1.68 | 4.87 | 304,929.80 | 4.82 | 8.66 | 8.95 | 13.79 | 69.08 | 68.60 | 9.27 | 16.07 | 0.3998 | 12.76 | 0.8294 | 100.64 | 8.24 | 2.69 | 186.18 | -10.32 | 7.69 | 1.57 |
| Sanofi SA | 35.43bn | 4.73bn | 89.82bn | 106.56k | 19.19 | -- | 13.74 | 2.54 | 3.75 | 2.95 | 28.14 | -- | -- | -- | -- | 332,482.40 | -- | 4.41 | -- | 5.20 | 67.90 | 68.20 | 13.31 | 13.07 | -- | 79.63 | -- | 86.67 | 4.31 | 0.137 | 13.40 | 0.3856 | 3.94 | 1.76 |
| Novo Nordisk A/S | 110.17bn | 38.73bn | 605.80bn | 42.69k | 20.15 | 17.50 | 14.45 | 5.50 | 15.72 | 15.72 | 44.71 | 18.10 | 1.17 | 1.14 | 6.61 | 2,618,452.00 | 41.25 | 38.64 | 81.78 | 67.69 | 84.05 | 84.18 | 35.15 | 32.27 | 0.7709 | -- | 0.0051 | 48.75 | -0.0752 | 7.44 | 0.5405 | 12.21 | 19.01 | 16.87 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2017 | 51.44m | 4.06% |
| The Vanguard Group, Inc.as of 01 Jun 2018 | 40.26m | 3.18% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2017 | 38.60m | 3.05% |
| Legal & General Investment Management Ltd.as of 01 Jun 2018 | 27.02m | 2.13% |
| Norges Bank Investment Managementas of 01 Jun 2018 | 26.42m | 2.09% |
| Dodge & Coxas of 01 Jun 2018 | 20.43m | 1.61% |
| Fidelity Management & Research Co.as of 01 Jun 2018 | 17.46m | 1.38% |
| BlackRock Fund Advisorsas of 01 Jun 2018 | 14.87m | 1.17% |
| Threadneedle Asset Management Ltd.as of 01 Jun 2018 | 14.02m | 1.11% |
| BlackRock Advisors (UK) Ltd.as of 01 Jun 2018 | 13.45m | 1.06% |
